Q-omics provides the consensus-scored TMEM88B profile across patient tissues and cancer cell-line models. TMEM88B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TMEM88B is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TMEM88B RNA expression shows 15,287 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, HNSC, and UVM as cancer lineages where TMEM88B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM88B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM88B survival associations across molecular data types. TMEM88B RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM88B RNA expression–survival associations across cancer types. High TMEM88B expression shows unfavorable associations in UCEC and COAD, but favorable associations in ESCA, LUAD, HNSC and UCS. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for TMEM88B RNA expression.
This table summarizes TMEM88B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM88B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM88B shows lower tumor expression in KIRP and KIRC and higher tumor expression in HNSC, LUAD, COAD and THCA. The HNSC box plot shows higher TMEM88B RNA expression in tumor versus normal tissue (log2 FC = +0.837, t-test p < 0.001).
This table shows molecular features associated with TMEM88B in patient tissues and cancer cell lines. In patient samples, TMEM88B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM88B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
